A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle

Updated 04/26/2024

Status Terminated

Clinical Trial Summary

This study is designed to evaluate the safety and efficacy of deflazacort in participants with LGMD2I. Most participants enrolled will have a screening visit and 3 additional visits (after 1, 13, and 26 weeks of treatment).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03783923
Study type	Interventional
Source	PTC Therapeutics
Contact
Status	Terminated
Phase	Phase 3
Start date	October 31, 2019
Completion date	January 1, 2021

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT01403402` - Congenital Muscle Disease Study of Patient and Family Reported Medical Information
	Completed	`NCT02635321` - MRI and Muscle Involvement in Patients With Mutations in GMPPB	N/A
	Completed	`NCT00873782` - Safety Study of Transvenous Limb Perfusion in Human Muscular Dystrophy	Phase 1
	Completed	`NCT00457912` - Genetic Characterization of Individuals With Limb Girdle Muscular Dystrophy	N/A
	Completed	`NCT04054375` - Weekly Steroids in Muscular Dystrophy	Phase 2
	Recruiting	`NCT00390104` - Molecular Analysis of Patients With Neuromuscular Disease
	Recruiting	`NCT06246513` - A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4 (EMERGENE)	Phase 3
	Completed	`NCT00104078` - Study Evaluating MYO-029 in Adult Muscular Dystrophy	Phase 1/Phase 2
	Recruiting	`NCT04475926` - A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice
	Completed	`NCT02759302` - MRI on Persons With Mutations in POMT2 Gene (LGMD2N)	N/A